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LYMPHOID NEOPLASIA
A shared gene expression signature in mouse models of EBV-associated and
non–EBV-associated Burkitt lymphoma
Kathryn T. Bieging,1 Kamonwan Fish,1 Subbarao Bondada,2 and Richard Longnecker1
1Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL; and 2Departments of Microbiology,
Immunology, and Molecular Genetics, Sanders Brown Center on Aging, Graduate Center for Toxicology, and Markey Cancer Center, University of Kentucky,
Lexington, KY
The link between EBV infection and
Burkitt lymphoma (BL) is strong, but the
mechanism underlying that link has been
elusive. We have developed a mouse
model for EBV-associated BL in which
LMP2A, an EBV latency protein, and MYC
are expressed in B cells. Our model has
demonstrated the ability of LMP2A to
accelerate tumor onset, increase spleen
size, and bypass p53 inactivation. Here
we describe the results of total gene
expression analysis of tumor and pretu-
mor B cells from our transgenic mouse
model. Although we see many pheno-
typic differences and changes in gene
expression in pretumor B cells, the tran-
scriptional profiles of tumor cells from
LMP2A/-MYC and -MYC mice are strik-
ingly similar, with fewer than 20 genes
differentially expressed. We evaluated the
functional significance of one of the most
interesting differentially expressed genes,
Egr1, and found that it was not required
for acceleration of tumor onset by LMP2A.
Our studies demonstrate the remarkable
ability of LMP2A to affect the pretumor
B-cell phenotype and tumorigenesis with-
out substantially altering gene expres-
sion in tumor cells. (Blood. 2011;118(26):
6849-6859)
Introduction
The connection between Epstein-Barr virus (EBV) and Burkitt
lymphoma (BL) led to identification of the virus 50 years ago, but
the mechanistic links between EBV and BL are still unclear.
Epidemiologic data reveal a strong association between EBV and
BL in regions of equatorial Africa where BL is endemic and has a
high incidence rate. EBV genomes can be found in nearly 100% of
endemic BL tumors. BL is also found at a lower incidence
worldwide in a form known as sporadic BL. Sporadic BL has a
lower association with EBV infection, with 15% to 85% of tumors
containing the virus, varying by region.1 BL is also a disease seen
in patients infected with HIV, where it has an intermediate
association with EBV infection. Regardless of the presence of
EBV, all forms of BL contain a translocation between the proto-
oncogene c-MYC and an Ig locus2,3 resulting in deregulated
expression of MYC in B lymphocytes. Clinically, a BL diagnosis is
based on the presence of the MYC translocation, a “starry sky”
histomorphology, which is the result of high levels of apoptosis
caused by overexpression of MYC in tumor cells, and immunophe-
notypic markers, such as CD10 and Bcl6. Distinguishing between
BL and diffuse large B cell lymphoma (DLBCL) can be difficult
because the diagnostic characteristics of the two tumors are quite
similar. Identification of gene expression signatures has proven to
be a very effective way to distinguish between the two lymphoma
types.4,5
Extensive studies comparing EBV and EBV BL tumors are
lacking. Until recently, the only existing data were based on BL cell
lines propagated in culture where they can acquire additional
molecular changes and may not be an accurate representation of the
molecular events that lead to tumorigenesis in vivo. However, a
recent study compared gene expression profiles among BL sub-
types, including endemic, sporadic, and HIV-associated BL samples.
Although the BL samples were clearly distinct from other B-cell
malignancies, distinguishing among BL subtypes was less precise,
and the samples did not cluster according to EBV status.6 There-
fore, the contributions of EBV to BL development are still not
clear.
The difficulty in elucidating the role of EBV in BL pathogenesis
can partly be attributed to limited viral gene expression in BL
tumors. EBV is known to adopt different patterns of latent viral
gene expression in infected cell lines and EBV-positive tumors.
The only viral protein that is easily detectable in BL tumor cells is
EBNA1, whose main function is to maintain the viral genome in an
infected cell.7 However, careful analyses have detected low levels
of another EBV latency protein, latent membrane protein 2A
(LMP2A) in BL biopsies.8,9 LMP2A is a membrane protein
containing an amino terminal cytoplasmic tail that provides
signaling capability. Tyrosine residues in the amino terminus have
been shown to interact with some of the same signaling molecules
that bind the B-cell receptor (BCR), such as the protein tyrosine
kinases Lyn and Syk.10,11 Many lines of evidence demonstrate the
pro-survival function of LMP2A, including the ability of LMP2A
to activate the Ras/PI3K/Akt pathway,12-14 the MAP kinase path-
way,15 NF-B,16 and Bcl-2 and Bcl-XL.13
Transgenic mice in which MYC is expressed from an Ig
promoter have been used as a model to study BL pathogenesis.17-19
These mice develop a fatal lymphoma within several months. We
developed a transgenic mouse model to study the role of LMP2A in
BL20,21 by crossing -MYC transgenic mice18 with mice that
express LMP2A in B cells.22,23 LMP2A/-MYC mice also develop
tumors, and tumor onset is accelerated compared with -MYC mice
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in two LMP2A transgenic lines.20,21 Alteration of the major tumor
suppressor p53 is common in tumors from MYC transgenic mice.19
However, the p53 pathway was functionally intact in LMP2A/-
MYC tumor cells.20 To investigate the functions of LMP2A in the
context of deregulated MYC and understand mechanism of accel-
eration of tumor onset and p53 bypass by LMP2A in our mouse
model of BL, we analyzed total gene expression in both tumor and
pretumor B cells from -MYC and LMP2A/-MYC mice. In
comparing expression profiles between pretumor B cells from
-MYC and LMP2A/-MYC mice, a large number of genes were
significantly differentially expressed. Remarkably, comparison of
-MYC and LMP2A/-MYC tumor B cells revealed very limited
differences in gene expression. Furthermore, one of the most
significantly differentially expressed genes, the transcription factor
Egr1, does not appear to be required for the phenotype of the
LMP2A/-MYC mice. These data support a model in which
LMP2A influences MYC-induced lymphomagenesis before progres-
sion to malignancy, and may do so post-translationally.
Methods
Mice
Construction and characterization of the ELMP2A transgenic mice have
been described previously.22,23 The ELMP2A Tg6 line23 was used in all
experiments. Double transgenic mice were generated by crossing the
Tg6-LMP2A line with previously characterized -MYC mice18 and domi-
nant negative Egr1 (DN Egr) transgenic mice.24 Mice were sacrificed when
cervical lymph node tumors could be observed externally and mice were
moribund. Animals were maintained at Northwestern University’s Center
for Comparative Medicine, in accordance with University animal welfare
guidelines, and approval was granted by the Northwestern University
Animal Care and Use Committee.
Tumor and spleen cell isolation
Pretumor spleens were isolated from 3-week-old mice. Magnetic activated
cell sorting using CD19 selection and negative selection B-cell isolation
kits were used to purify B cells (Miltenyi Biotec). Pretumor spleens (those
used for FACS analysis of total splenocytes) and cervical lymph node
tumors were dissociated between frosted glass slides and treated with
155mM ammonium chloride to lyse red blood cells.
Flow cytometry
Total pretumor splenocytes and cervical lymph node tumor cells were
stained with B220-allophycocyanin (APC), IgM-PE, or CD43-PE fluoro-
chrome-conjugated antibodies (BD Biosciences). Purified B cells from
pretumor spleens were stained with B220-APC, fixed with 1% paraformal-
dehyde, and stored in 70% ethanol at 20°C overnight. Cells were then
stained with propidium iodide/RNase staining buffer according to the
manufacturer’s instructions (BD Biosciences). All samples were analyzed
using the LSRII flow cytometer and FACS Diva Version 6.1 software (BD
Biosciences).
Histology
Spleens from 3-week-old mice or cervical lymph node tumors were fixed in
10% buffered formalin phosphate (Fisher Scientific) followed by paraffin
embedding. Tissues were sectioned and stained with hematoxylin and eosin
at the Mouse Histology and Phenotyping Laboratory at Northwestern
University. Stained tissue sections were imaged using a Leica DMR upright
microscope and AxioCam MRC camera with AxioVision Rel 4.6 acquisi-
tion software.
RNA preparation and microarray experiments
Total RNA was isolated from tumor or pretumor cells using RNeasy RNA
extraction kit from QIAGEN. RNA samples were amplified, labeled, and
hybridized at the Genomics Core Facility at the Center for Genetic
Medicine at Northwestern University according to Illumina protocols.
MouseRef-8 Version 2.0 Expression Bead Chips (Illumina) were used for
all experiments. An Illumina iScan was used to scan the arrays. The primary
expression profiling data are available at the National Center for Biotechnol-
ogy Information Gene Expression Omnibus under the accession number
GSE26918.
Statistical analysis
GeneSpringGX analysis software (Agilent Technologies) was used for the
microarray data analysis. The quantile normalization method was used for
preprocessing, and the baseline was set to the median of all samples. The
detection P value was used to eliminate probes that were not significantly
expressed in any sample. Probes were excluded from the analysis if none of
the samples had a detection P value  .95. To identify significant probes,
the Benjamini-Hochberg false discovery rate was used for the multiple
testing correction P value. Probes with a P value  .05 and a fold change of
 1.5 were considered significant.
Real time RT-PCR
Total RNA was isolated from tumor or pretumor cells using RNeasy RNA
extraction kit from QIAGEN. Reverse transcription using a High-Capacity
cDNA Reverse Transcription kit from Applied Biosystems was used to
generate cDNA. Real-time PCR was carried out on Applied Biosystems
Step One Plus machine using primers specific for the indicated gene as well
as Hprt or Gapdh. Fast SYBR Green master mix from Applied Biosystems
was used in all reactions. The Ct method was used to normalize gene
expression to Hprt or Gapdh.
Immunoblots
Tumor cells were lysed in modified RIPA buffer (0.1M Tris-HCl pH 8.2,
0.15M NaCl, 2% SDS, 1% NP40 alternate, 0.5% Na-deoxycholate, 0.01M
NaF, 0.002M Na3VO4, 0.002M phenylmethylsulfonyl floride, 0.01M DTT)
with protease and phosphatase inhibitor cocktails (Roche Diagnostics).
DNA and nucleic acid were digested with Benzonase nuclease (Sigma-
Aldrich). Lysates were cleared and heated for 10 minutes at 72°C and then
electrophoretically separated by 10% SDS-PAGE. Protein was transferred
to Immobilon-P membrane (Millipore) and probed for Egr1 and Gapdh
(Abcam).
Results
The EBV-associated BL mouse model phenotype
To study the contributions of EBV LMP2A to BL pathogenesis, we
have used two LMP2A transgenic mouse models. In the TgE-
LMP2A transgenic line, LMP2A is expressed at a high level.23 The
TgE line demonstrates altered B-cell development, as expression of
LMP2A allows survival of IgM cells in the periphery.22 The
Tg6-LMP2A transgenic line expresses lower levels of LMP2A, and
B-cell development is normal in these mice.23,25 Using either of
these models, LMP2A accelerates tumor onset in -MYC trans-
genic mice.20,21 In this report, we focus on the Tg6-LMP2A
transgenic line, from here simply referred to as LMP2A transgenic.
Although B-cell development is normal in Tg6-LMP2A transgenic
mice23 (Figure 1A), crossing the LMP2A transgenic line with
-MYC transgenic mice results in an altered developmental pheno-
type. Figure 1A shows the cell surface phenotype of splenocytes
from 3-week-old littermates. In wild-type and LMP2A transgenic
mice, most B220 splenocytes also express IgM. However, B220
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B cells do not express high levels of CD43, a marker expressed on
pro-B and pre-BI but down-regulated on pre-BII cells (Figure 1A).
At 3 weeks of age, development is slightly delayed in the -MYC
mice, where the spleens contain relatively fewer IgM B cells and
more CD43 B cells (Figure 1A). By 6 weeks of age, the
immunophenotype of -MYC B cells is not different from wild-
type (data not shown). We have previously reported that LMP2A/-
MYC mice have enlarged spleens,20,21 which can be observed as
early as 3 weeks of age. In contrast to wild-type, LMP2A
transgenic, or -MYC mice, B220 B cells in LMP2A/-MYC
spleens lack expression of IgM and show high CD43 expression
(Figure 1A). Figure 1A shows representative plots from individual
mice. Tabulated data on the average percentage of cells that fall
into B220, IgM, or CD43 (quadrant 1), B220, IgM, or
CD43 (quadrant 2), B220, IgM, or CD43 (quadrant 3), and
B220, IgM, or CD43 (quadrant 4) for 7 to 14 mice per genotype
is shown in Tables 1 and 2.
Splenic architecture is altered in LMP2A/-MYC mice. H&E
staining of spleen sections from 3-week-old littermates reveal
organized structures, and the beginnings of follicle development
can be observed in wild-type, LMP2A transgenic, and -MYC mice
(Figure 1B). LMP2A/-MYC spleens, however, are much more
disorganized, and follicle structures are rarely observed (Figure
1B). Examination of cell cycle profiles in purified B cells from
Figure 1. Pretumor transgenic mouse phenotypes. (A) Total splenocytes were harvested from 3-week-old littermates, stained with B220-APC (y-axis) and IgM-PE or
CD43-PE (x-axis), and analyzed by flow cytometry. The percentage B220, IgM, or CD43 (Q1), B220, IgM, or CD43 (Q2), B220, IgM, or CD43 (Q3), and B220,
IgM, or CD43 (Q4) is indicated for each genotype. Data are presented for individual mice but are representative of 7 to 14 mice analyzed per genotype (see also summarized
data in Tables 1 and 2). (B) Spleens of the indicated genotype were fixed in 10% buffered formalin phosphate followed by paraffin embedding. Spleens were then sectioned and
stained with H&E. The beginning of normal splenic structures can be observed (see arrows), with the LMP2A/-MYC spleen less organized. The rectangles in the left-hand
column represent the area that is magnified in the right-hand column. (C) Spleens were isolated from 3-week-old littermates, and B cells were purified using a MACS protocol
with magnetic beads specific for the B-cell marker CD19. Purified B cells were fixed with paraformaldehyde and ethanol and then stained with propidium iodide (x-axis) to
measure the percentage of cycling cells. Cells were analyzed by flow cytometry to measure the percentage of cells that fall into the sub G0, G0/G1, or S/G2/M gates.
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transgenic littermates also revealed differences in LMP2A/-MYC
mice. B cells from both LMP2A/-MYC and -MYC mice show a
considerable population of cycling cells with DNA content greater
than 2n consistent with the MYC transgene driving cell cycle
progression. However, a greater proportion of B cells from
LMP2A/-MYC spleens fall into the S/G2/M gate of proliferating
cells (Figure 1C). These data are consistent with a previous report
of TgE-LMP2A/-MYC mice.21
The EBV-associated BL tumor phenotype
Cervical lymph node tumor cells from LMP2A/-MYC mice are
nearly all B220 B lymphocytes (Figure 2A). The immunopheno-
type of the tumor cells is similar to B cells from the spleens of
3-week-old mice in that the tumor B cells express no surface IgM
and high levels of CD43 (Figure 2A). Tumors from -MYC mice
are also nearly all B220 B cells. The -MYC tumor cells are often
IgM, consistent with previous reports,18 although we also observe
IgM -MYC tumors (Figure 2A). Tables 3 and 4 show tabulated
data on the average percentage of cells that fall into B220, IgM
or CD43 (quadrant 1), B220, IgM or CD43 (quadrant 2),
B220, IgM, or CD43 (quadrant 3), and B220, IgM, or
CD43 (quadrant 4) for cervical lymph node tumors. More than
90% of tumor cells from LMP2A/-MYC mice (n 	 18) are
B220, IgM (Tables 3 and 4).
The histology of the LMP2A/-MYC and -MYC tumors is of
particular interest. H&E-stained tissue sections of tumors from
both LMP2A/-MYC and -MYC genotypes display a “starry sky”
pattern that is similar to the histopathology of human BL tumors
(Figure 2B).18 The “starry sky” appearance is not seen in spleens
from 3-week-old littermates (Figure 1B). Importantly, we can use
the same criteria used by clinicians to diagnose BL in human
patients to distinguish between “tumor” and “pretumor” animals in
our mouse model. In our analysis, “pretumor” B cells are isolated
from the spleens of 3-week-old mice in which the “starry sky”
histopathology is absent. We define “tumor” B cells as those
isolated from the cervical lymph node of tumor-burdened trans-
genic mice in which the “starry sky” phenotype is observed.
Expression profiling of EBV-associated and non–EBV-
associated BL
Illumina gene expression arrays were used to analyze total gene
expression in B cells from our transgenic mice. RNA from both
tumor and pretumor samples were included in the analysis. B cells
were purified from the spleens of 3-week-old (pretumor) mice, and
tumor B cells were isolated from the cervical lymph nodes of
tumor-bearing mice. Both IgM and IgM -MYC tumor samples
were included. The gene array chips purchased from Illumina
contained approximately 25 000 probe sequences corresponding to
more than 19 000 unique genes. Genes were considered differen-
tially expressed if they had a fold change greater than 1.5 and an
altered P value of  .05 by the Benjamini-Hochberg false
discovery rate calculation.
No significant differences in gene expression were measured in
comparing B cells from LMP2A mice with wild-type mice.
However, comparison of gene expression profiles of pretumor
B cells from LMP2A/-MYC and -MYC mice revealed substantial
differences. Figure 3A shows the heat map of 199 probe sequences
that are differentially expressed by our statistical parameters. These
199 probes correspond to 187 unique genes, 77 of which are
up-regulated in the LMP2A/-MYC pretumor B cells, whereas
110 are down-regulated in the LMP2A/-MYC pretumor B cells
(relative to expression in -MYC B cells). The list of up-regulated
genes, their fold change differences and P values can be found in
supplemental Table 1 (available on the Blood Web site; see the
Supplemental Materials link at the top of the online article) and the
list of down-regulated genes in supplemental Table 2. To validate
the differential expression of genes identified by microarray
analysis, the expression level of a few of the genes in supplemental
Tables 1 and 2 was examined by real-time RT-PCR. Quantitative
PCR with primers specific for Egr1, Nfkbid, Rin3, and CD80
confirmed the statistically significant increase in expression of
these genes in LMP2A/-MYC pretumor cells. Statistically signifi-
cant decreased expression of Myl4, IL7R, and VpreB in LMP2A/-
MYC pretumor cells was also confirmed (Figure 4A).
In contrast to our analysis of pretumor B cells, comparison of
the gene expression profiles of tumor B cells from LMP2A/-MYC
and -MYC mice showed that tumor cells from the two groups are
transcriptionally quite similar. Only 19 probes met our statistical
cut-off for differential expression (Figure 3B). These 19 probes
correspond to 17 unique genes. Twelve genes are up-regulated in
the LMP2A/-MYC tumor B cells, and 5 genes are down-regulated
in the LMP2A/-MYC tumor B cells (Table 5). Again, we
confirmed the differential expression of several targets by real-time
RT-PCR. LMP2A/-MYC tumor cells showed statistically signifi-
cant elevated expression of Rin3, Pdlim7, s100a10, Bbc3, and
Egr1, whereas expression of Ddit4 was decreased compared with
Table 2. Flow cytometric analysis of total splenocytes from 3-week-old mice: CD43 and B220
Q1: B220,
CD43
Q2:
B220,CD43
Q3: B220,
CD43
Q4: B220,
CD43
WT (n 	 6) 47.0 
 4.7 13.6 
 5.0 15.1 
 9.9 24.3 
 6.8
Tg6 LMP2A (n 	 12) 33.7 
 7.4 10.0 
 3.3 19.2 
 12.3 37.2 
 10.0
-MYC (n 	 10) 24.5 
 9.8 30.2 
 9.8 20.0 
 8.7 25.3 
 11.9
LMP2A/-MYC (n 	 12) 3.4 
 1.8 70.9 
 11.4 14.6 
 6.3 11.2 
 6.3
Values are percentages.
Table 1. Flow cytometric analysis of total splenocytes from 3-week-old mice: IgM and B220
Q1: B220,
IgM
Q2: B220,
IgM
Q3: B220,
IgM
Q4: B220,
IgM
WT (n 	 7) 14.8 
 6.4 42.6 
 7.4 41.7 
 9.0 0.9 
 0.5
Tg6 LMP2A (n 	 13) 12.3 
 4.3 30.6 
 11.0 56.2 
 10.4 0.8 
 0.4
-MYC (n 	 14) 30.5 
 10.5 22.8 
 5.9 45.7 
 13.4 1.0 
 0.9
LMP2A/-MYC (n 	 14) 73.5 
 10.9 1.2 
 1.0 25.0 
 11.2 0.3 
 0.2
Values are percentages.
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-MYC (Figure 4B). Increased expression of Egr1 protein was
confirmed by immunoblot (Figure 4C).
The relatively short list of differentially regulated genes identi-
fied in comparing the gene expression profiles of LMP2A/-MYC
and -MYC tumor B cells is surprising because of the fairly
dramatic phenotypes observed in the LMP2A/-MYC mice, such as
acceleration of tumor onset and bypass of p53 inactivation.20 The
more slowly arising -MYC tumors may be more heterogeneous
than LMP2A/-MYC tumors, which could result in more variation
among their gene expression profiles. Increased heterogeneity of
-MYC tumors could contribute to the small number of differen-
tially expressed genes identified in the tumor comparison. How-
ever, clear subgroups within -MYC tumor samples could not be
delineated, even if the samples were separated by IgM expression
or p53 status, or when additional -MYC tumor samples were
included. One interpretation of the small number of target genes
Figure 2. Phenotype of transgenic mouse tumors.
(A) Cervical lymph node tumor cells were harvested from
tumor-burdened mice and stained with B220-APC
(y-axis) and IgM-PE or CD43-PE (x-axis) and analyzed
by flow cytometry. The percentage of cells that fall within
each quadrant is indicated. Both IgM (n 	 7) and IgM
(n 	 5) -MYC tumors are observed, and an example of
each is shown. All LMP2A/-MYC tumors are IgM
(n 	 18; see also summarized quadrant data in Tables 3
and 4). (B) Cervical lymph node tumors were isolated
from tumor-burdened mice and fixed in 10% buffered
formalin phosphate followed by paraffin embedding. Tu-
mors were then sectioned and stained with hematoxylin
and eosin. Note the “starry sky” pattern that is also
characteristic of human Burkitt lymphoma tumors.
Table 3. Flow cytometric analysis of cervical lymph node tumor cells: IgM and B220
Q1: B220,
IgM
Q2: B220,
IgM
Q3: B220,
IgM
Q4: B220,
IgM
LMP2A/-MYC CT (n 	 18) 95.4 
 3.4 0.8 
 0.6 3.7 
 3.3 0.1 
 0.1
-MYC CT (IgM) (n 	 7) 30.7 
 26.4 68.2 
 25.7 1.0 
 0.9 0.2 
 0.2
-MYC CT (IgM) (n 	 5) 96.7 
 2.6 1.3 
 1.5 1.8 
 1.8 0.1 
 0.1
Values are percentages.
Table 4. Flow cytometric analysis of cervical lymph node tumor cells: CD43 and B220
Q1: B220,
CD43
Q2: B220,
CD43
Q3: B220,
CD43
Q4: B220,
CD43
LMP2A/-MYC CT (n 	 17) 9.4 
 10.2 86.8 
 10.0 0.3 
 0.3 3.5 
 3.7
-MYC CT (IgM) (n 	 7) 14.4 
 27.3 83.9 
 27.4 0.2 
 0.4 1.5 
 1.8
-MYC CT (IgM) (n 	 5) 3.8 
 3.6 93.6 
 4.1 0.4 
 0.4 2.1 
 1.9
Values are percentages.
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identified in comparing LMP2A/-MYC and -MYC tumors is that
these genes are particularly important for the effects of LMP2A in
the presence of deregulated MYC.
Egr1 in LMP2A/-MYC tumors
The gene with the largest fold change value in comparing gene
expression in LMP2A/-MYC and -MYC tumor B cells is early
growth response gene-1 (Egr1, Figure 4B; Table 5). Egr1 expres-
sion was also increased at the protein level in LMP2A/-MYC
tumors (Figure 4C), and in LMP2A/-MYC pretumor B cells
compared with -MYC pretumor B cells (Figure 4A; supplemental
Table 1). We were particularly interested in this gene for several
reasons. First, Egr1 is known to be differentially expressed in some
types of human cancer. For example, increased Egr1 expression is
commonly observed in prostate cancer cells,26,27 and Egr1 is
important for progression to malignancy in prostate cancer cell
lines28-30 and mouse models.31 The Egr1 gene encodes a transcrip-
tion factor expressed in many cell types whose function depends on
cell type and context; Egr1 is known to function in cell differentia-
tion, growth promotion and growth suppression, and apoptosis.32-34
Egr1 belongs to the immediate early gene family and is rapidly
induced in response to various stimuli, including growth factors,
cytokines, and irradiation, varying by cell type.32,35-37 In B cells,
Egr1 is induced by BCR signaling.24,33,38 Given that LMP2A is a
signaling molecule that is functionally similar to the BCR,10,11,22 we
hypothesized that induction of Egr1 in LMP2A/-MYC mice may
contribute to their accelerated tumorigenesis.20,21 To test the
functional importance of Egr1 in our transgenic model, we used a
transgenic mouse expressing a DN Egr in B cells.24 The DN Egr
used in our studies consists of a truncated version of the Egr1
protein, containing only the DNA binding domain, which is
expressed from an Ig promoter, targeting expression to B cells. The
dominant negative has been shown to inhibit the functions of all
Egr family members and subtly alter B-cell differentiation and
responses to BCR ligation.24
We generated triple transgenic mice expressing LMP2A, MYC,
and DN Egr in B cells. LMP2A/-MYC/DN Egr mice and
-MYC/DN Egr mice both develop lymph node tumors, and these
tumors contain similar levels of DN Egr mRNA (Figure 5A). To
verify function of the DN Egr transgene, we examined expression
of two established transcriptional targets of Egr1 in B cells, CD44
and Icam-1.39,40 Consistent with previous studies,24 unstimulated
B cells from DN Egr transgenic mice have reduced expression of
CD44 as well as Icam-1 relative to wild-type B cells (Figure 5B-C).
Levels of both CD44 and Icam-1 were slightly higher, though not
statistically significant, in tumor cells from LMP2A/-MYC rela-
tive to -MYC tumors. These results are consistent with our
demonstration of Egr1 up-regulation in LMP2A/-MYC tumors
(Figures 3 and 4). Furthermore, tumor cells from both -MYC/DN
Egr and LMP2A/-MYC/DN Egr mice show significantly down-
regulated expression of CD44 and Icam-1 relative to wild-type
B cells. These data suggest that the DN Egr transgene is functional
in the LMP2A/-MYC and -MYC tumor models, inhibiting
transcriptional targets of endogenous Egr1. To assess the role of
Egr1 in acceleration of tumor onset by LMP2A, we monitored
cohorts of transgenic mice. Tumor mortality in the LMP2A/-
MYC/DN Egr mice was no different from the tumor mortality we
observed in LMP2A/-MYC mice (Figure 5D). Similarly, tumor
onset in -MYC/DN Egr transgenic mice was not different from
-MYC mice (Figure 5D). Taken together, these results demon-
strate that functional inhibition of Egr1 does not affect tumorigen-
esis in LMP2A/-MYC mice, suggesting that induction of Egr1 is
not responsible for acceleration of tumor onset by LMP2A.
Figure 3. Differentially expressed probe sequences in tumor and pretumor B
cells. Data analysis was performed using GeneSpringGX software. Probes were
included if the fold change was greater than 1.5 and false discovery rate (adjusted P value)
 .05. (A) A total of 199 probe sequences are differentially expressed in pretumor B cells.
The 199 probes correspond to 187 unique genes, 77 are up-regulated in the LMP2A/-
MYC samples, and 110 are down-regulated in the LMP2A/-MYC samples. (B) Nineteen
probe sequences are differentially expressed in cervical lymph node tumor samples. The
19 probes correspond to 17 unique genes, 12 are up-regulated in the LMP2A/-MYC
samples, and 5 are down-regulated in the LMP2A/-MYC samples.
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Discussion
Gene expression profiling is a powerful tool that can be used to
categorize, clarify the origins, and potentially even identify the
underlying causes of malignancies. We analyzed total gene expres-
sion in a transgenic mouse model for EBV-associated BL. There
are some major phenotypic differences in tumors from LMP2A/-
MYC and -MYC mice. The tumors differ in IgM expression
(Figure 2A) and p53 status,20 each of which could heavily
influence gene expression. However, our results show that gene
expression in LMP2A/-MYC and -MYC tumors is surprisingly
similar. Some of the differentially expressed genes are consis-
tent with known characteristics of LMP2A/-MYC tumors,
supporting the validity of our analysis. For example, Bbc3,
which encodes Puma, a proapoptotic p53 target gene, showed
increased expression in LMP2A/-MYC tumors, consistent with
a previous report.20 Ddit4 or DNA damage inducible transcript 4
was significantly down-regulated in LMP2A/-MYC tumors
(Figures 3 and 4; Table 5). Ddit4 is also known as REDD1 and
functions to modulate an important cell growth pathway by
negatively regulating mammalian target of rapamycin (mTOR).
In a tumor transfer model, LMP2A/-MYC tumors were more
dependent on the mTOR pathway and more effectively treated
with rapamycin relative to -MYC tumors.41
One of the most interesting differentially expressed genes
identified in our studies was the transcription factor Egr1. The
importance of Egr1 in regulating expression of many genes
Figure 4. Validation of selected targets in pretumor and tumor B cells. RNA was isolated from purified B cells from 3-week-old -MYC and LMP2A/-MYC mice (A) or
cervical lymph node tumor cells from tumor-burdened -MYC and LMP2A/-MYC mice (B) and converted to cDNA. Real-time RT-PCR analysis was performed using primers
specific for the indicated target gene as well as the housekeeping gene Hprt. Each bar represents the average Ct for at least 3 different mice, and the Ct was calculated
using one of the 3 individual -MYC mice as the reference sample to set the baseline for each gene. Error bars represent SEM. *P  .05. ***P  .01. (C) Immunoblot analysis
shows Egr1 expression in tumor cells from LMP2A/-MYC mice and -MYC mice. Each lane represents a single tumor of the indicated genotype, and the data are
representative of several immunoblot analyses.
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involved in cell survival, growth, and differentiation32-34 suggested
to us that Egr1 may be important for the ability of LMP2A to
accelerate tumor onset in the presence of deregulated MYC. That
Egr1 induction is downstream of BCR signaling24,33,38 and LMP2A
can be described as a BCR signaling “mimic” leant further support
to our hypothesis. However, Egr1 function, at least the amount that
could be blocked by expression of a dominant negative Egr,24
does not appear to be required for tumor acceleration by LMP2A
(Figure 5).
In contrast to LMP2A/-MYC and -MYC tumors, we see a
much greater difference in gene expression in LMP2A/-MYC and
-MYC pretumor B cells (Figure 6), with a 10-fold increase in the
number of differentially expressed genes. The increase in differen-
tial gene expression in pretumor mice is probably largely associ-
ated with the phenotypic differences between LMP2A/-MYC and
-MYC mice that can be observed at early ages. Before tumors arise
in these mice, we see differences in B-cell development (Figure
1A), spleen size,21 splenic architecture (Figure 1B), and cell cycle
profiles (Figure 1C).21 Although B-cell development is not altered
in the Tg6-LMP2A transgenic line used in these studies23 (Figure 1)
and microarray analysis comparing the Tg6-LMP2A transgenic
line to wild-type mice showed no differences in gene expression
in the absence of BCR activation,42 here we show that, in the
presence of overexpressed MYC, even low levels of LMP2A
expression from the Tg6 transgene23 have a great impact on
B-cell development.
A closer look at some of the individual genes that are
differentially expressed in pretumor B cells demonstrates the
influence of altered B-cell development on gene expression. The
gene with the highest fold-change is Vpreb1 (supplemental Table 2;
Figure 4), which is down-regulated in LMP2A/-MYC pretumor B
cells. Vpreb1 is a component of the pre-BCR, previously shown to
be altered by LMP2A in bone marrow cells.15 Dntt, terminal
deoxynucleotidyltransferase, was also reduced in LMP2A/-MYC
pretumor B cells (supplemental Table 2). Expression of both of
these developmentally regulated targets was previously shown
to be altered by LMP2A in the TgE line43 but was not changed in
the Tg6-LMP2A line.42 The high amount of surface B220 and
CD43 (Figure 1A) coupled with the absence of surface IgM
(Figure 1A) and reduced levels of VpreB1 and Dntt mRNA
suggest that B cells in the LMP2A/-MYC mice may be arrested
at the pro-B to pre-B stage of development. Interestingly,
mRNA levels of the IL-7 receptor are also reduced in LMP2A/-
MYC pretumor B cells (supplemental Table 2; Figure 4).
Expression of IL-7R is also developmentally regulated as IL-7
receptor signaling is required for survival of early B-cell
populations in the bone marrow, and pro-B cells generally
express high levels of IL-7R. In our mice, the combination of the
survival pathways activated by LMP2A13,22 and proliferative
pathways activated by MYC may preclude the requirement for
signaling through either the preBCR or IL-7R during early
stages of B-cell development.
The pretumor B cells also have altered expression of some
signaling molecules, including Pik3cd, Inpp5d, Plcd3, and
Mapk12 (supplemental Tables 1-2). LMP2A has been shown to
activate numerous signaling pathways12-15 that are generally
regulated through post-translational protein modification. In
light of the striking transcriptional similarity between LMP2A/
-MYC and -MYC tumors, further investigation of the differ-
ences between LMP2A/-MYC and -MYC tumors at the protein
or post-translational level is needed. Such studies may be
helpful in identifying cellular proteins or pathways that are
required for the role of LMP2A in tumorigenesis and lead to
identification of novel drug targets for EBV-associated
malignancies.
We can use our gene expression analysis of LMP2A/-MYC and
-MYC tumors to enhance our overall understanding of the role of
EBV in BL. The transition from a normal B cell to a tumor cell
requires multiple cellular changes. In human BL, after the MYC
translocation, mutation in p53 is a common genetic change found
in tumor biopsies.44,45 In our study, we see massive changes in gene
expression when comparing LMP2A/-MYC pretumor B cells with
LMP2A/-MYC tumor B cells (1196 probes) or -MYC pretumor
B cells to -MYC tumor B cells (1763 probes; Figure 6). In MYC
transgenic mice that express LMP2A, tumor onset is faster,20,21 and
we do not find mutations in p53.20 In addition, fewer changes in
gene expression occur in the transition from a pretumor B cell to a
tumor B cell (Figure 6). However, once tumors develop in
LMP2A/-MYC or -MYC mice, gene expression in B cells is
only minimally different. The similarity in gene expression
Table 5. Significantly up-regulated and down-regulated genes in LMP2A/-MYC tumors
Symbol Definition Fold change P False discovery rate
Up-regulated genes
Egr1 Early growth response 1 3.6304 .0000135 0.0239
Rin3 Ras and Rab interactor 3 2.5029 .000115 0.0430
Ear2 Eosinophil-associated, ribonuclease A family, member 2 2.2655 .0000292 0.0330
Ear4 Eosinophil-associated, ribonuclease A family, member 4 2.0558 .00013 0.0448
Capn2 Calpain 2 1.9949 .000116 0.0430
Plscr1 Phospholipid scramblase 1 1.9808 .000017 0.0249
Bbc3 BCL2 binding component 3 1.9007 .0000921 0.0429
Pdlim7 PDZ and LIM domain 7 1.7375 .0000884 0.0429
S100a10 S100 calcium binding protein A10 (calpactin) 1.7371 .000106 0.0429
Bcor Bcl6 interacting corepressor (Bcor), transcript variant a 1.6400 .000142 0.0469
Nfat5 Nuclear factor of activated T-cells 5 1.5846 .0000906 0.0429
1810009N02Rik RIKEN cDNA 1810009N02 gene 1.5233 .0000069 0.0239
Down-regulated genes
Tob1 Transducer of ErbB-2.1 1.5070 .0000857 0.0429
LOC100045019 Predicted: Mus musculus similar to tubulin, gamma 2 1.5685 .0000481 0.0378
5830405N20Rik RIKEN cDNA 5830405N20 gene 1.9015 .000104 0.0429
Arhgap22 Rho GTPase activating protein 22 2.0540 .0000303 0.0330
Ddit4 DNA-damage-inducible transcript 4 3.1498 .0000681 0.0429
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profiles supports our proposed model for the role of EBV in
BL.46 Our model purports that LMP2A is most important early
in tumorigenesis by promoting survival in the presence of
deregulated MYC while additional cellular changes are ac-
quired. These same changes may also occur in non–EBV-
associated BL, but the presence of LMP2A increases the
likelihood that an additional “hit” will occur in a cell that
overexpresses MYC. After tumor progression, dependence on
LMP2A decreases and EBV and EBV tumor cells lack
significant transcriptional differences. The similarity between
EBV-associated and non–EBV-associated BL has resulted in
difficulty in understanding the function(s) of EBV in BL
development. Here we have shown that the LMP2A/-MYC
model reflects this puzzle, revealing nearly identical gene
expression profiles in LMP2A and LMP2A tumors. These
data highlight the utility of the mouse model in understanding
human BL pathogenesis and developing drug targets for human
disease.
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